HILDEN, Germany and GERMANTOWN, Maryland, April 13, 2016 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with Mirati Therapeutics, Inc. (NASDAQ: MRTX) to co-develop and commercialize a companion diagnostic test to guide the use of Mirati's glesatinib (MGCD265), a targeted therapy under development for non-small cell lung cancer (NSCLC). The companies aim to create a regulator-approved test to personalize treatment decisions in NSCLC by detecting RNA biomarkers produced by exon 14 skipping mutations of the MET gene.

"We are pleased to partner with Mirati to commercialize a standardized companion diagnostic paired with glesatinib, a compound now in Phase II trials for NSCLC patients with cancer-driving MET alterations. Delivering insights on these clinically actionable variants holds potential to significantly improve clinical outcomes," said Peer M. Schatz, Chief Executive Officer of QIAGEN. "This companion diagnostic for glesatinib is the initial effort under a master collaboration agreement and we continue to discuss potential future projects across various sample types and platforms, such as PCR and NGS, to further expand targeted diagnostic capabilities in this arena."

Click here [https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID=%7bF2DBB7F8-F394-4B2E-87AE-5A72DB7994D2%7d&lang=en ] for full press release 


        
         
        Public Relations:

         
        Dr. Thomas Theuringer 
        Director Public Relations 
        +49-2103-29-11826 
        Email: pr@qiagen.com 
        http://www.twitter.com/qiagen  
        https://www.facebook.com/QIAGEN  
        pr.qiagen.com

         
        Investor Relations:

         
        John Gilardi 
        Vice President Corporate Communications and Investor Relations 
        +49-2103-29-11711 
        Email: ir@qiagen.com 
        ir.qiagen.com 

 

SOURCE QIAGEN N.V.